In contrast to these local treatments, the systemic administration of recombinant human IFN-γ in patients with acute myeloblastic leukemia and myelodysplastic syndromes did not lead to hematological responses and was only poorly tolerated [38]. This evidence concerns the gene IFNG and myelodysplastic syndrome.